Welcome to Ashvattha
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases. We believe that HDTs will become the future of targeted therapeutics and unlock new levels of patient care.
Our solution enables patient selection followed by treatment with anti-neuroinflammatory agent coupled to HDT to target reactive microglia
We have designed and optimized an HDT that precisely targets reactive macrophages and retinal pigment epithelial cells (RPEs) after systemic administration
Neurologists test novel compound for lung and brain injury in severe COVID-19 patients (UT Health News)
Neurologists are researching whether a novel immunomodulatory treatment, OP-101, an investigational compound developed by Ashvattha Therapeutics, can dampen lung and brain injury in hospitalized COVID-19 patients through a clinical trial at The University of Texas Health Science Center at Houston.
Ashvattha Therapeutics Announces Positive Interim Data from Ongoing Phase 2 PRANA Clinical Study of OP-101 in Severe COVID-19 Patients
Ashvattha announced positive interim results from its ongoing multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hyperinflammation in hospitalized adults with severe COVID-19.
Ashvattha will present at the Sachs 7th Annual Immuno-Oncology Innovation Forum, held virtually on May 18-20
Ashvattha Therapeutics Presents Transformative Anti-Angiogenesis Treatment for Retinal Disorders at ARVO 2021
Ashvattha announced the presentation of a virtual poster supporting the development of its proprietary HDT, D-4517, for treatment of AMD at the 2021 ARVO Annual Meeting.
Ashvattha Therapeutics Announces Collaboration with Stanford University for Preclinical Development of a Novel Neuroimaging Agent, OP-801
Ashvattha initiates a preclinical proof of concept study for OP-801 imaging of neuroinflammation. This Investigational New Drug (IND)-enabling research will be conducted in collaboration with a team of researchers at the Stanford University School of Medicine led by Michelle James, Ph.D., Assistant Professor of Radiology and Neurology.